Baker Bros. Advisors LP Madrigal Pharmaceuticals, Inc. Transaction History
Baker Bros. Advisors LP
- $9.86 Billion
- Q2 2025
A detailed history of Baker Bros. Advisors LP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 1,976,018 shares of MDGL stock, worth $709 Million. This represents 6.06% of its overall portfolio holdings.
Number of Shares
1,976,018
Previous 1,974,590
0.07%
Holding current value
$709 Million
Previous $654 Million
8.57%
% of portfolio
6.06%
Previous 7.8%
Shares
9 transactions
Others Institutions Holding MDGL
# of Institutions
354Shares Held
23.3MCall Options Held
745KPut Options Held
476K-
Janus Henderson Group PLC London, X02.19MShares$787 Million0.34% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.09MShares$750 Million32.86% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$716 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.88MShares$674 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.88MShares$673 Million10.35% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $6.14B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...